ABROCITINIB (Cibinqo ®)

Clinical Indication

Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy

Comments

Not yet reviewed

Date of classification

October 2021

Review date

October 2021

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.